Phosphocreatine |
Catalog No.GC36898
One-Click Copy Product Info
|
Phosphocreatine is a high-energy phosphate compound that is abundant in muscle and brain.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 67-07-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Phosphocreatine is a high-energy phosphate compound that is abundant in muscle and brain [1]. Under non-steady-state conditions, Phosphocreatine maintains the ATP homeostasis at specific high-energy turnover sites (such as muscle fibers), especially in rapidly contracting skeletal muscles, and prevents a significant increase in the intracellular free ADP concentration, thereby minimizing the loss of intracellular adenosine nucleotides [2]. Phosphocreatine has been widely used to alter lipid phase transitions, influencing the aggregation of membranes and protecting cell membranes from various damages[3].
In vitro, Phosphocreatine treatment (30mM) for 2 hours significantly inhibited the apoptosis of human umbilical vein endothelial cells (HUVECs) induced by oxidized low-density lipoprotein (oxLDL), and reduced the loss of mitochondrial membrane permeability [4]. Phosphocreatine (5mM) treatment for 4 hours significantly inhibited the increase in intracellular reactive oxygen species (ROS) in rat striatal slices induced by 6-hydroxydopamine, restored the level of tyrosine hydroxylase (TH), and reduced cell death[5]. 500μM Phosphocreatine pretreatment for 1 hour significantly inhibited doxorubicin (1μM; 24h)-induced necrotic cell death in H9c2 cells, accompanied by a decrease in the expression of RIP3 and CaMKII[6].
In vivo, Phosphocreatine treatment via intraperitoneal injection at a dose of 20mg/kg/day for 8 weeks significantly improved the renal function of the diabetic-nephropathy fibrosis rat model, inhibited renal inflammation, and restored mitochondrial function[7]. Intraperitoneal injection of 40mg/kg/day dose of Phosphocreatine for 6 weeks significantly alleviated renal damage in the diabetic rat model and lowered blood glucose levels[8].
References:
[1] Chen L, Schär M, Chan K W Y, et al. In vivo imaging of phosphocreatine with artificial neural networks[J]. Nature communications, 2020, 11(1): 1072.
[2] Greenhaff P L. The creatine-phosphocreatine system: there's more than one song in its repertoire[J]. The Journal of physiology, 2001, 537(Pt 3): 657.
[3] Tokarska-Schlattner M, Epand R F, Meiler F, et al. Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects[J]. 2012.
[4] Ahsan A, Han G, Pan J, et al. Phosphocreatine protects endothelial cells from oxidized low-density lipoprotein-induced apoptosis by modulating the PI3K/Akt/eNOS pathway[J]. Apoptosis, 2015, 20(12): 1563-1576.
[5] Cunha M P, Martín-de-Saavedra M D, Romero A, et al. Both creatine and its product phosphocreatine reduce oxidative stress and afford neuroprotection in an in vitro Parkinson’s model[J]. ASN neuro, 2014, 6(6): 1759091414554945.
[6] Wang C, Hu L, Guo S, et al. Phosphocreatine attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and activating TAK1 to promote myocardial survival in vivo and in vitro[J]. Toxicology, 2021, 460: 152881.
[7] Wang F H, Alwesabi A K, Liu W, et al. Phosphocreatine Attenuates Diabetes-Exacerbated Kidney Fibrosis via TGF-β/Smad and PI3K/Akt Pathways in a Dual Rat Model[J]. Tissue and Cell, 2026: 103439.
[8] Shopit A, Niu M, Wang H, et al. Protection of diabetes-induced kidney injury by phosphocreatine via the regulation of ERK/Nrf2/HO-1 signaling pathway[J]. Life sciences, 2020, 242: 117248.
| Cell experiment [1]: | |
|
Cell lines |
Human umbilical vein endothelial cells (HUVECs) |
|
Preparation Method |
HUVECs were incubated in DMEM medium supplemented with 10% fetal calf serum (FCS) in a humidified atmosphere at 37°C with 5% CO2. Cells were plated at a density of 2×104/well in a 96-well tissue culture plate for 24h and preincubated with various concentrations of Phosphocreatine (0, 10, 20, 30mM) for 2h, then cells were stimulated with 200µg/ml oxLDL for 24h in the presence of Phosphocreatine. The cell viability of HUVECs was determined. |
|
Reaction Conditions |
0, 10, 20, 30mM; preincubated for 2h |
|
Applications |
Phosphocreatine treatment significantly reduced oxLDL-induced death of HUVECs in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Sprague-Dawley rats |
|
Preparation Method |
Male Sprague-Dawley rats (180-200g) were housed in controlled conditions (22±2°C, 50-70% humidity, 12-hour light/dark cycle) with unlimited access to standard commercial feed and water. Rats were acclimatized for one week before the investigation. Diabetes was induced through a single intraperitoneal injection of Streptozotocin at a dose of 50mg/kg. Hyperglycemia was confirmed when fasting blood glucose exceeded 250mg/dl. Kidney fibrosis was induced through unilateral ureteral obstruction (UUO) performed under anesthesia. Diabetic fibrotic rats treated with Phosphocreatine (20mg/kg/day; intraperitoneally) for 8 weeks, starting one week after UUO. Collect the renal tissues of rats for analysis. |
|
Dosage form |
20mg/kg/day for 8 weeks; i.p. |
|
Applications |
Phosphocreatine treatment significantly improved the renal function of the diabetic-nephropathy fibrosis rat models. |
|
References: |
|
| Cas No. | 67-07-2 | SDF | |
| Canonical SMILES | O=C(O)CN(C(NP(O)(O)=O)=N)C | ||
| Formula | C4H10N3O5P | M.Wt | 211.11 |
| Solubility | Water : 100mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.7369 mL | 23.6843 mL | 47.3687 mL |
| 5 mM | 947.4 μL | 4.7369 mL | 9.4737 mL |
| 10 mM | 473.7 μL | 2.3684 mL | 4.7369 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >90.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)